Angelman Syndrome: all 52 studies

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)RecruitingNCT07782827Phase 3
• BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.RecruitingNCT07605429Phase 3
• A Natural History Study of Angelman SyndromeRecruitingNCT07417137
• A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman SyndromeRecruitingNCT07181837Phase 1/2
• Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman SyndromeAvailableNCT07136454
• Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman SyndromeRecruitingNCT06737718
• Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With EpilepsyRecruitingNCT06353620
• Study of the Prevalence of Autistic Traits in Angelman SyndromeRecruitingNCT06337383
• Natural History Study for Patients With Angelman SyndromeRecruitingNCT06229769
• Angelman Natural History Study - FAST SpainRecruitingNCT06115109
• IDMet (RaDiCo Cohort) (RaDiCo-IDMet)RecruitingNCT05945576
• The Global Angelman Syndrome RegistryRecruitingNCT05293184
• Angelman Syndrome Natural History Study-FAST UKRecruitingNCT05100810
• Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or ObesityRecruitingNCT04768803
• Angelman Syndrome Natural History StudyRecruitingNCT04507997
• Parent and Infant Inter(X)Action Intervention (PIXI)Enrolling by invitationNCT03836300Not applicable
• A Study of OV101 in Individuals With Angelman Syndrome (AS)CompletedNCT04106557Phase 3Results posted
• An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromeTerminatedNCT03882918Phase 3Results posted
• A Study in Adults and Adolescents With Angelman Syndrome (STARS)CompletedNCT02996305Phase 2Results posted
• Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment DisabilitiesCompletedNCT01906866Phase 3Results posted
• Minocycline in the Treatment of Angelman SyndromeCompletedNCT01531582Not applicableResults posted
• A Trial of Levodopa in Angelman SyndromeCompletedNCT01281475Phase 2/3Results posted
• Study on Tolerability of Levodopa/Carbidopa in Children With Angelman SyndromeCompletedNCT00829439Phase 1Results posted
• Dietary Supplements for the Treatment of Angelman SyndromeCompletedNCT00348933Not applicableResults posted
• A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)TerminatedNCT07157254Phase 2
• REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromeActive, not recruitingNCT06914609Phase 3
• Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)TerminatedNCT06617429Phase 3
• Long-term Extension of GTX-102 in Angelman SyndromeTerminatedNCT06415344Phase 3
• Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)Active, not recruitingNCT06139172Not applicable
• Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi SyndromeCompletedNCT05783791
• Angelman Syndrome Video Assessment (ASVA) Source Material StudyCompletedNCT05637697
• A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.CompletedNCT05630066Phase 2
• HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeActive, not recruitingNCT05127226Phase 1/2
• An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman SyndromeCompletedNCT05011851Phase 2
• A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male ParticipantsCompletedNCT04863794Phase 1
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)CompletedNCT04428281Phase 1
• A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeCompletedNCT04259281Phase 1/2
• Angelman Syndrome (AS) Biomarker StudyCompletedNCT04103333Early Phase 1
• Early Check: Expanded Screening in NewbornsActive, not recruitingNCT03655223
• Italian Angelman Syndrome RegistryCompletedNCT03650569
• Nutritional Formulation for Angelman SyndromeCompletedNCT03644693Not applicable
• Study on the Brain Network of Angelman SyndromeCompletedNCT03358823
• Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man SyndromeCompletedNCT03235037Not applicable
• Single Dose Pharmacokinetic (PK) StudyCompletedNCT03109756Phase 1
• Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PWCompletedNCT02670694
• SNP-based Microdeletion and Aneuploidy RegisTry (SMART)CompletedNCT02381457
• An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum DisorderWithdrawnNCT02226458Phase 2
• Study to Evaluate the Efficacy and Safety of Minocycline in Angelman SyndromeCompletedNCT02056665Phase 2
• Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep DisturbancesCompletedNCT01903681Phase 1
• Genomic Imprinting and Assisted Reproductive TechnologiesCompletedNCT00773825
• Characterization of Angelman SyndromeCompletedNCT00296764
• Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion SyndromesCompletedNCT00004351

← Angelman Syndrome overview